ELSEVIER

Toxicology Letters 82/83 (1995) 981–987

Toxicology Letters

Author index

Volumes 82/83 (1995)

Agrawal, S., P.K. Rustagi, D.R. Shaw, Novel enzymatic and immunological responses to oligonucleotides **82/83**, 431
Aguzzi, A., see Kleihues, P. **82/83**, 601
Aizawa, S., see Kamataki, T. **82/83**, 879
Allen, B.C., see Kimmel, C.A. **82/83**, 549
Anandatheerthavarada, H.K., see Ravindranath, V. **82/83**, 633
Andersen, M.E., Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs **82/83**, 341
Asamoto, M., see Tsuda, H. **82/83**, 693
Ashley, D.L., see Needham, L.L. **82/83**, 373
Atterstam, I., Media and risk communication **82/83**, 211
Aust, S.D., Ferritin as a source of iron and protection from iron-induced toxicities **82/83**, 941
Auton, T.R., see Foster, P.M.D. **82/83**, 555

Baba-Toriyama, H., see Tsuda, H. **82/83**, 693
Bachowski, S., see Klaunig, J.E. **82/83**, 683
Bacon, J.A., see Ulrich, R.G. **82/83**, 107
Badawi, A.F., see Kadlubar, F.F. **82/83**, 627
Baker, T.K., see Klaunig, J.E. **82/83**, 683
Balmain, A., see Brown, K. **82/83**, 123
Barsig, J., see Bohlinger, I. **82/83**, 227
Bartsch, I., see Glatt, H. **82/83**, 829
Bastlova, T., see Lambert, B. **82/83**, 323
Baud, F.J., S.W. Borron, C. Bismuth, Modifying toxicokinetics with antidotes **82/83**, 785
Baudrimont, I., see Creppy, E.E. **82/83**, 869
Baylin, S.B., see Belinsky, S.A. **82/83**, 335
Belinsky, S.A., K.J. Nikula, S.B. Baylin, J.-P. Issa, A microassay for measuring cytosine DNA methyltransferase activity during tumor progression **82/83**, 335 Bellamine, A., see Pompon, D. **82/83**, 815
Bergh, A., see Strobel, H.W. **82/83**, 639
Berman, H.A., see Taylor, P. **82/83**, 453
Berry, C., Can chemicals be loved? — A problem for 2000 **82/83**, 725
Betbeder, A.-M., see Creppy, E.E. **82/83**, 869
Bhagwat, S.V., see Ravindranath, V. **82/83**, 633
Bhamre, S., see Ravindranath, V. **82/83**, 633
Birnbaum, L.S., Developmental effects of dioxins and related endocrine disrupting chemicals **82/83**, 743
Bismuth, C., see Baud, F.J. **82/83**, 785
Blake, B.L., see Hodgson, E. **82/83**, 73
Blumenthal, G.M., see Welsch, F. **82/83**, 539
Bock, K.-W., see Schwarz, M. **82/83**, 27
Boelens, R., see Kaptein, R. **82/83**, 591
Bogdanffy, M.S., A.M. Jarabek, Understanding mechanisms of inhaled toxicants: implications for replacing default factors with chemical-specific data **82/83**, 919
Bohlinger, I., M. Leist, J. Barsig, S. Uhlig, G. Tiegs, A. Wendel, Tolerance against tumor necrosis factor α (TNF)-induced hepatotoxicity in mice: the role of nitric oxide **82/83**, 227
Bond, J.A., M.A. Medinsky, Health risk assessment of chemical mixtures from a research perspective **82/83**, 521
Boorman, G.A., R.C. Sills, S. Grumbein, R. Hailey, R.A. Miller, R.A. Herbert, Long-term toxicity studies of ozone in F344/N rats and B6C3F1 mice **82/83**, 301
Borghoff, S.J., see Butterworth, B.E. **82/83**, 23
Borowitz, J.L., see Isom, G.E. **82/83**, 795
Borron, S.W., see Baud, F.J. **82/83**, 785
Bosshard, H.R., see Przybylski, M. **82/83**, 567
Bromberg, P.A., H.S. Koren, Ozone-induced human respiratory dysfunction and disease **82/83**, 307
Brooks, S.M., Occupational asthma **82/83**, 39
Brown, K., P.A. Burns, A. Balmain, Transgenic approaches to understanding the mechanisms of chemical carcinogenesis in mouse skin **82/83**, 123
Bruccoleri, A., see Luster, M.I. **82/83**, 471
Brüne, B., U.K. Meßmer, K. Sandau, The role of nitric oxide in cell injury **82/83**, 233
Buchmann, A., see Schwarz, M. **82/83**, 27
Buringh, E., see van Bree, L. **82/83**, 317
Burleson, F.G., see Luster, M.I. **82/83**, 471
Burns, P.A., see Brown, K. **82/83**, 123
Bursch, W., see Schulte-Hermann, R. **82/83**, 143
Büsselberg, D., Calcium channels as target sites of heavy metals **82/83**, 255

0378-4274/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

Butterworth, B.E., M.V. Templin, S.J. Borghoff, R.B. Conolly, G.L. Kedderis, D.C. Wolf, The role of regenerative cell proliferation in chloroform-induced cancer **82/83**, 23
Butterworth, B.E., see Conolly, R.B. **82/83**, 901

Cabral, R., see Ferrer, A. **82/83**, 55
Camp, S., see Taylor, P. **82/83**, 453
Carter, D.B., see Narahashi, T. **82/83**, 239
Carter, J.M., see Driscoll, K.E. **82/83**, 483
Carthew, P., see Smith, A.G. **82/83**, 945
Cassee, F.R., see Feron, V.J. **82/83**, 505
Cecchelli, R., see Ghersi-Egea, J.F. **82/83**, 645
Clothier, B., see Smith, A.G. **82/83**, 945
Cohen, G.M., see Fearnhead, H.O. **82/83**, 135
Cohen, S.M., Role of cell proliferation in regenerative and neoplastic disease **82/83**, 15
Conolly, R.B., B.E. Butterworth, Biologically based dose response model for hepatic toxicity: a mechanistically based replacement for traditional estimates of noncancer risk **82/83**, 901
Conolly, R.B., see Butterworth, B.E. **82/83**, 23
Conolly, R.B., see Welsch, F. **82/83**, 539
Constan, A.A., see Yang, R.S.H. **82/83**, 497
Constantin, D., see Smith, A.G. **82/83**, 945
Cook, J.A., see Wink, D.A. **82/83**, 221
Copple, B.L., see Iversen, P.L. **82/83**, 425
Counts, J.L., J.I. Goodman, Hypomethylation of DNA: a nongenotoxic mechanism involved in tumor promotion **82/83**, 663
Cramer, C.T., see Ulrich, R.G. **82/83**, 107
Creppy, E.E., I. Baudrimont, A.-M. Betbeder, Prevention of nephrotoxicity of ochratoxin A, a food contaminant **82/83**, 869
Csanády, G.A., see Filser, J.G. **82/83**, 357
Cunningham, M.L., H.B. Matthews, Cell proliferation as a determining factor for the carcinogenicity of chemicals: studies with mutagenic carcinogens and mutagenic noncarcinogens **82/83**, 9
Czich, A., see Glatt, H. **82/83**, 829

Daughtrey, W.C., see White, R.D. **82/83**, 719
De Gregorio, L., see Dragani, T.A. **82/83**, 613
de Loos, S., see van Bree, L. **82/83**, 317
Dearman, R.J., see Kimber, I. **82/83**, 491
Denda, A., T. Endoh, D. Nakae, Y. Konishi, Effects of oxidative stress induced by redox-enzyme modulation on rat hepatocarcinogenesis **82/83**, 413
Dinsdale, D., see Fearnhead, H.O. **82/83**, 135
Doehmer, J., A. Schneider, M. Faßbender, V. Soballa, W.A. Schmalix, H. Greim, Genetically engineered mammalian cells and applications **82/83**, 823
Doehmer, J., see Stadler, J. **82/83**, 215
Dorman, D.C., see Medinsky, M.A. **82/83**, 707
Doroshow, J.H., Glutathione peroxidase and oxidative stress **82/83**, 395
Dragani, T.A., G. Manenti, M. Gariboldi, L. De Gregorio, M.A. Pierotti, Genetics of liver tumor susceptibility in mice **82/83**, 613
Driscoll, K.E., D.G. Hassenbein, J.M. Carter, S.L. Kunkel, T.R. Quinlan, B.T. Mossman, TNFα and increased chemokine expression in rat lung after particle exposure **82/83**, 483
Dürr, E., see Przybylski, M. **82/83**, 567

El-Masri, H.A., see Yang, R.S.H. **82/83**, 497
Ellinger, A., see Schulte-Hermann, R. **82/83**, 143
Endoh, T., see Denda, A. **82/83**, 413
Everitt, J.I., T.L. Goldsworthy, D.C. Wolf, C.L. Walker, Hereditary renal cell carcinoma in the Eker rat: a unique animal model for the study of cancer susceptibility **82/83**, 621

Fahey, J.W., see Talalay, P. **82/83**, 173
Falany, C.N., see Glatt, H. **82/83**, 829
Falls, G., see Hodgson, E. **82/83**, 73
Farmer, P.B., Monitoring of human exposure to carcinogens through DNA and protein adduct determination **82/83**, 757
Faßbender, M., see Doehmer, J. **82/83**, 823
Faustman, E.M., see Kimmel, C.A. **82/83**, 549
Fearnhead, H.O., M. MacFarlane, D. Dinsdale, G.M. Cohen, DNA degradation and proteolysis in thymocyte apoptosis **82/83**, 135
Felton, J.S., see Thompson, L.H. **82/83**, 883
Fenstermacher, J.D., see Ghersi-Egea, J.F. **82/83**, 645
Fernandez-Salguero, P., see Gonzalez, F.J. **82/83**, 117
Feron, V.J., J.P. Groten, J.A. van Zorge, F.R. Cassee, D. Jonker, P.J. van Bladeren, Toxicity studies in rats of simple mixtures of chemicals with the same or different target organs **82/83**, 505
Ferrer, A., R. Cabral, Recent epidemics of poisoning by pesticides **82/83**, 55
Feyereisen, R., Molecular biology of insecticide resistance **82/83**, 83
Filser, J.G., G.A. Csanády, P.E Kreuzer, W. Kessler, Toxicokinetic models for volatile industrial chemicals and reactive metabolites **82/83**, 357
Fischer, P.H., see van Bree, L. **82/83**, 317
Foster, P.M.D., T.R. Auton, Application of benchmark dose risk assessment methodology to developmental toxicity: an industrial view **82/83**, 555
Fox, D.A., D. Srivastava, Molecular mechanism of the lead-induced inhibition of rod cGMP phosphodiesterase **82/83**, 263
Fox, G.B., see Murphy, K.J. **82/83**, 271
Francis, J.E., see Smith, A.G. **82/83**, 945
Frey, J., see Narahashi, T. **82/83**, 239
Friedman, M., see Pryor, W.A. **82/83**, 287
Fubini, B., L. Mollo, Role of iron in the reactivity of mineral fibers **82/83**, 951
Fürstenberger, G., see Marks, F. **82/83**, 907

Gaido, K., see Luster, M.I. **82/83**, 471
Gariboldi, M., see Dragani, T.A. **82/83**, 613
Gautier, J.-C., see Pompon, D. **82/83**, 815
Geng, J., see Strobel, H.W. **82/83**, 639
Germolec, D.R., see Luster, M.I. **82/83**, 471
Gescher, A., Modulators of signal transduction as cancer chemotherapeutic agents novel mechanisms and toxicities **82/83**, 159
Ghersi-Egea, J.F., B. Leininger-Muller, R. Cecchelli, J.D. Fenstermacher, Blood-brain interfaces: relevance to cerebral drug metabolism **82/83**, 645
Ginsburg, K., see Narahashi, T. **82/83**, 239
Glatt, H., I. Bartsch, A. Czich, A. Seidel, C.N. Falany, *Salmonella* strains and mammalian cells genetically engineered for expression of sulfotransferases **82/83**, 829
Glocker, M.O., see Przybylski, M. **82/83**, 567
Glynn, P., see Johnson, M.K. **82/83**, 459
Goldsworthy, T.L., see Everitt, J.I. **82/83**, 621
Goldsworthy, T.L., see Recio, L. **82/83**, 607
Gonzalez, F.J., P. Fernandez-Salguero, S.S.T. Lee, T. Pineau, J.M. Ward, Xenobiotic receptor knockout mice **82/83**, 117
Goodman, J.I., see Counts, J.L. **82/83**, 663
Grasl-Kraupp, B., see Schulte-Hermann, R. **82/83**, 143
Greim, H., see Doehmer, J. **82/83**, 823
Groopman, J.D., T.W. Kensler, J.M. Links, Molecular epidemiology and human risk monitoring **82/83**, 763
Groten, J.P., see Feron, V.J. **82/83**, 505
Grumbein, S., see Boorman, G.A. **82/83**, 301
Gustafsson, J., Receptor-mediated toxicity **82/83**, 465

Hagiwara, A., see Ito, N. **82/83**, 513
Hailey, R., see Boorman, G.A. **82/83**, 301
Hamilton, B.J., see Narahashi, T. **82/83**, 239
Hammond, T.G., C.N. Kind, Pancreatic and nephrotoxicity of immunomodulator compounds **82/83**, 99
Harris, C.C., 1995 Deichmann Lecture p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment **82/83**, 1
Hasegawa, R., see Ito, N. **82/83**, 513
Hashimoto, H., see Kamataki, T. **82/83**, 879
Hassenbein, D.G., see Driscoll, K.E. **82/83**, 483
Hattori, K., see Kamataki, T. **82/83**, 879
Heinzelmann, T., see Marks, F. **82/83**, 907
Henderson, R.F., Strategies for use of biological markers of exposure **82/83**, 379
Herbert, R.A., see Boorman, G.A. **82/83**, 301
Hider, R.C., Potential protection from toxicity by oral iron chelators **82/83**, 961
Hirose, M., see Ito, N. **82/83**, 513
Hodgson, A.V., see Strobel, H.W. **82/83**, 639
Hodgson, E., R.L. Rose, D.-Y. Ryu, G. Falls, B.L. Blake, P.E. Levi, Pesticide-metabolizing enzymes **82/83**, 73
Holliday, M.R., see Kimber, I. **82/83**, 491
Holtzclaw, W.D., see Talalay, P. **82/83**, 173
Hori, T., see Tsuda, H. **82/83**, 693
Hosea, N.A., see Taylor, P. **82/83**, 453
Hosokawa, M., see Satoh, T. **82/83**, 439
Hou, S.-M., see Lambert, B. **82/83**, 323
Hsu, V.L., X. Jia, D.R. Kearns, Multidimensional NMR spectroscopy of DNA-binding proteins: structure and function of a transcription factor **82/83**, 577

Ibach, B., see Volk, B. **82/83**, 655
Ichikawa, K., see Utsumi, H. **82/83**, 561
Imaida, K., see Ito, N. **82/83**, 513
Isenberg, J.S., see Klaunig, J.E. **82/83**, 683
Isom, G.E., J.L. Borowitz, Modification of cyanide toxicodynamics: mechanistic based antidote development **82/83**, 795
Issa, J.-P., see Belinsky, S.A. **82/83**, 335
Ito, N., A. Hagiwara, S. Tamano, R. Hasegawa, K. Imaida, M. Hirose, T. Shirai, Lack of carcinogenicity of pesticide mixtures administered in the diet at acceptable daily intake (ADI) dose levels in rats **82/83**, 513
Itoh, S., see Kamataki, T. **82/83**, 879
Iversen, P.L., B.L. Copple, H.K. Tewary, Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man **82/83**, 425
Iwahori, Y., see Tsuda, H. **82/83**, 693
Iwatsubo, T., see Suzuki, H. **82/83**, 349

Jarabek, A.M., see Bogdanffy, M.S. **82/83**, 919
Jenkins, C.M., see Waterman, M.R. **82/83**, 807
Jia, X., see Hsu, V.L. **82/83**, 577
Johanson, G., A. Nihlén, A. Löf, Toxicokinetics and acute effects of MTBE and ETBE in male volunteers **82/83**, 713
Johnson, M.K., P. Glynn, Neuropathy target esterase (NTE) and organophosphorus-induced delayed polyneuropathy (OPIDP): recent advances **82/83**, 459
Jonker, D., see Feron, V.J. **82/83**, 505

Kadlubar, F.F., A.F. Badawi, Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis **82/83**, 627
Kamataki, T., H. Hashimoto, M. Shimoji, S. Itoh, K. Nakayama, K. Hattori, T. Yokoi, M. Katsuki, S. Aizawa, Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice **82/83**, 879
Kaneko, H., see Miyamoto, J. **82/83**, 933
Kaptein, R., M. Slijper, R. Boelens, Structure and dynamics of the *lac* repressor-operator complex as determined by NMR **82/83**, 591
Kast, J., see Przybylski, M. **82/83**, 567
Katsuki, M., see Kamataki, T. **82/83**, 879
Kavlock, R.J., see Kimmel, C.A. **82/83**, 549
Kawashima, H., see Strobel, H.W. **82/83**, 639
Kearns, D.R., see Hsu, V.L. **82/83**, 577
Kedderis, G.L., see Butterworth, B.E. **82/83**, 23
Kelly, J., see Murphy, K.J. **82/83**, 271
Kensler, T.W., see Groopman, J.D. **82/83**, 763
Kessler, W., see Filser, J.G. **82/83**, 357

Ketcham, C.A., see Klaunig, J.E. **82/83**, 683
Keyler, D.E., see Pentel, P.R. **82/83**, 801
Kim, D.J., see Tsuda, H. **82/83**, 693
Kimber, I., M.R. Holliday, R.J. Dearman, Cytokine regulation of chemical sensitization **82/83**, 491
Kimmel, C.A., R.J. Kavlock, B.C. Allen, E.M. Faustman, The application of benchmark dose methodology to data from prenatal developmental toxicity studies **82/83**, 549
Kind, C.N., see Hammond, T.G. **82/83**, 99
Klaunig, J.E., Y. Xu, S. Bachowski, C.A. Ketcham, J.S. Isenberg, K.L. Kolaja, T.K. Baker, E.F. Walborg Jr., D.E. Stevenson, Oxidative stress in nongenotoxic carcinogenesis **82/83**, 683
Kleeberger, S.R., Genetic susceptibility to ozone exposure **82/83**, 295
Kleihues, P., A. Aguzzi, H. Ohgaki, Genetic and environmental factors in the etiology of human brain tumors **82/83**, 601
Knoth, R., see Volk, B. **82/83**, 655
Koike, K., see Matsukura, M. **82/83**, 435
Kolaja, K.L., see Klaunig, J.E. **82/83**, 683
Konishi, Y., see Denda, A. **82/83**, 413
Koren, H.S., see Bromberg, P.A. **82/83**, 307
Kreuzer, P.E, see Filser, J.G. **82/83**, 357
Krieger, R.I., Pesticide exposure assessment **82/83**, 65
Krishna, M.C., see Wink, D.A. **82/83**, 221
Krishnan, V., see Safe, S. **82/83**, 731
Krutovskikh, V., see Mesnil, M. **82/83**, 701
Kuiper-Goodman, T., Mycotoxins: risk assessment and legislation **82/83**, 853
Kunkel, S.L., see Driscoll, K.E. **82/83**, 483

La, D.K., see Swenberg, J.A. **82/83**, 751
Laine, R., see Pompon, D. **82/83**, 815
Lake, B.G., Peroxisome proliferation: current mechanisms relating to non-genotoxic carcinogenesis **82/83**, 673
Lambert, B., T. Bastlova, A.-M. Österholm, S.-M. Hou, Analysis of mutation at the *hprt* locus in human T lymphocytes **82/83**, 323
Lee, S.S.T., see Gonzalez, F.J. **82/83**, 117
Lees-Haley, P.R., Neurobehavioral assessment in toxic injury evaluations **82/83**, 197
Leininger-Muller, B., see Ghersi-Egea, J.F. **82/83**, 645
Leist, M., see Bohlinger, I. **82/83**, 227
Levi, P.E., see Hodgson, E. **82/83**, 73
Levin, A.A., Receptors as tools for understanding the toxicity of retinoids **82/83**, 91
Liebmann, J., see Wink, D.A. **82/83**, 221
Links, J.M., see Groopman, J.D. **82/83**, 763
Löf, A., see Johanson, G. **82/83**, 713
Loikkanen, J., see Savolainen, K.M. **82/83**, 399
Looney, R.J., see Utell, M.J. **82/83**, 47
Luster, M.I., J.L. Wilmer, D.R. Germolec, J. Spalding, T. Yoshida, K. Gaido, P.P. Simeonova, F.G. Burleson, A. Bruccoleri, Role of keratinocyte-derived cytokines in chemical toxicity **82/83**, 471

MacFarlane, M., see Fearnhead, H.O. **82/83**, 135
Madra, S., see Smith, A.G. **82/83**, 945
Manenti, G., see Dragani, T.A. **82/83**, 613
Marchot, P., see Taylor, P. **82/83**, 453
Marks, F., G. Fürstenberger, T. Heinzelmann, K. Müller-Decker, Mechanisms in tumor promotion: guidance for risk assessment and cancer chemoprevention **82/83**, 907
Marra, M., see van Bree, L. **82/83**, 317
Matsukura, M., K. Koike, G. Zon, Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) **82/83**, 435
Matthews, H.B., see Cunningham, M.L. **82/83**, 9
Maurissen, J.P.J., A few considerations in the design and analysis of experiments in neurotoxicology **82/83**, 187
Medinsky, M.A., D.C. Dorman, Recent developments in methanol toxicity **82/83**, 707
Medinsky, M.A., see Bond, J.A. **82/83**, 521
Mehendale, H.M., Injury and repair as opposing forces in risk assessment **82/83**, 891
Meßmer, U.K., see Brüne, B. **82/83**, 233
Mesnil, M., V. Krutovskikh, Y. Omori, H. Yamasaki, Role of blocked gap junctional intercellular communication in nongenotoxic carcinogenesis **82/83**, 701
Meyer, R.P., see Volk, B. **82/83**, 655
Miller, F.J., Uptake and fate of ozone in the respiratory tract **82/83**, 277
Miller, R.A., see Boorman, G.A. **82/83**, 301
Mirsalis, J.C., Transgenic models for detection of mutations in tumors and normal tissues of rodents **82/83**, 131
Mitchell, J.B., see Wink, D.A. **82/83**, 221
Miyamoto, J., H. Kaneko, R. Tsuji, Y. Okuno, Pyrethroids, nerve poisons: how their risks to human health should be assessed **82/83**, 933
Mollo, L., see Fubini, B. **82/83**, 951
Mossman, B.T., see Driscoll, K.E. **82/83**, 483
Müllauer, L., see Schulte-Hermann, R. **82/83**, 143
Müller-Decker, K., see Marks, F. **82/83**, 907
Mumtaz, M.M., Risk assessment of chemical mixtures from a public health perspective **82/83**, 527
Murphy, K.J., G.B. Fox, J. Kelly, C.M. Regan, Influence of toxicants on neural cell adhesion molecule-mediated neuroplasticity in the developing and adult animal: persistent effects of chronic perinatal low-level lead exposure **82/83**, 271
Mutai, M., see Tsuda, H. **82/83**, 693

Naarala, J., see Savolainen, K.M. **82/83**, 399
Nagata, K., see Narahashi, T. **82/83**, 239
Nakae, D., see Denda, A. **82/83**, 413
Nakayama, K., see Kamataki, T. **82/83**, 879
Narahashi, T., D.B. Carter, J. Frey, K. Ginsburg, B.J. Hamilton, K. Nagata, M.L. Roy, J.-H. Song, H. Tatebayashi, Sodium channels and $GABA_A$ receptor-channel complex as targets of environmental toxicants **82/83**, 239
Nau, H., Chemical structure — teratogenicity relationships, toxicokinetics and metabolism in risk assessment of retinoids **82/83**, 975

Navarra, P., P. Puccetti, C. Riccardi, P. Preziosi, Anticancer drug toxicity via cytokine production: the hydroxyurea paradigm **82/83**, 167
Neal, G.E., Genetic implications in the metabolism and toxicity of mycotoxins **82/83**, 861
Needham, L.L., D.L. Ashley, D.G. Patterson Jr., Case studies of the use of biomarkers to assess exposures **82/83**, 373
Neumann, H.-G., C. van Dorp, I. Zwirner-Baier, The implications for risk assessment of measuring the relative contribution to exposure from occupation, environment and lifestyle: hemoglobin adducts from amino- and nitroarenes **82/83**, 771
Nihlén, A., see Johanson, G. **82/83**, 713
Nikula, K.J., see Belinsky, S.A. **82/83**, 335
Nobel, I., see Slater, A.F.G. **82/83**, 149
Nock, S., see Przybylski, M. **82/83**, 567

O'Flaherty, E.J., PBK modeling for metals. Examples with lead, uranium, and chromium **82/83**, 367
Ohgaki, H., see Kleihues, P. **82/83**, 601
Okuno, Y., see Miyamoto, J. **82/83**, 933
Omori, Y., see Mesnil, M. **82/83**, 701
Orrenius, S., see Slater, A.F.G. **82/83**, 149
Österholm, A.-M., see Lambert, B. **82/83**, 323

Pacelli, R., see Wink, D.A. **82/83**, 221
Patterson Jr., D.G., see Needham, L.L. **82/83**, 373
Peng, G.W., see Ulrich, R.G. **82/83**, 107
Pentel, P.R., D.E. Keyler, Drug-specific antibodies as antidotes for tricyclic antidepressant overdose **82/83**, 801
Perret, A., see Pompon, D. **82/83**, 815
Petrella, D.K., see Ulrich, R.G. **82/83**, 107
Pierotti, M.A., see Dragani, T.A. **82/83**, 613
Pikuleva, I., see Waterman, M.R. **82/83**, 807
Pineau, T., see Gonzalez, F.J. **82/83**, 117
Pompon, D., A. Perret, A. Bellamine, R. Laine, J.-C. Gautier, P. Urban, Genetically engineered yeast cells and their applications **82/83**, 815
Prestera, T., see Talalay, P. **82/83**, 173
Preziosi, P., see Navarra, P. **82/83**, 167
Proudfoot, A.T., Antidotes: benefits and risks **82/83**, 779
Pryor, W.A., G.L. Squadrito, M. Friedman, A new mechanism for the toxicity of ozone **82/83**, 287
Przybylski, M., J. Kast, M.O. Glocker, E. Dürr, H.R. Bosshard, S. Nock, M. Sprinzl, Mass spectrometric approaches to molecular characterization of protein-nucleic acid interactions **82/83**, 567
Puccetti, P., see Navarra, P. **82/83**, 167

Quinlan, T.R., see Driscoll, K.E. **82/83**, 483

Radic, Z., see Taylor, P. **82/83**, 453
Ravindranath, V., S. Bhamre, S.V. Bhagwat, H.K. Anandatheerthavarada, S.K. Shankar, P.S. Tirumalai, Xenobiotic metabolism in brain **82/83**, 633
Recio, L., T.L. Goldsworthy, The use of transgenic mice for studying mutagenicity induced by 1,3-butadiene **82/83**, 607
Reed, J.C., Bcl-2 family proteins: regulators of chemoresistance in cancer **82/83**, 155
Regan, C.M., see Murphy, K.J. **82/83**, 271
Reiner, E., V. Simeon-Rudolf, M. Skrinjaric-Spoljar, Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera **82/83**, 447
Riccardi, C., see Navarra, P. **82/83**, 167
Rombout, P.J.A., see van Bree, L. **82/83**, 317
Rose, R.L., see Hodgson, E. **82/83**, 73
Roy, M.L., see Narahashi, T. **82/83**, 239
Rustagi, P.K., see Agrawal, S. **82/83**, 431
Ryffel, B., Role of proinflammatory cytokines in a toxin response: application of cytokine knockout mice in toxicological research **82/83**, 477
Ryu, D.-Y., see Hodgson, E. **82/83**, 73

Safe, S., V. Krishnan, Chlorinated hydrocarbons: estrogens and antiestrogens **82/83**, 731
Samet, J.M., Asthma and the environment: do environmental factors affect the incidence and prognosis of asthma? **82/83**, 33
Sandau, K., see Brüne, B. **82/83**, 233
Satoh, T., M. Hosokawa, Molecular aspects of carboxylesterase isoforms in comparison with other esterases **82/83**, 439
Savolainen, K.M., J. Loikkanen, J. Naarala, Amplification of glutamate-induced oxidative stress **82/83**, 399
Scheller, N.A., see Swenberg, J.A. **82/83**, 751
Schmalix, W.A., see Doehmer, J. **82/83**, 823
Schmalix, W.A., see Stadler, J. **82/83**, 215
Schmitz, M.L., Function and activation of the transcription factor NF-κB in the response to toxins and pathogens **82/83**, 407
Schneider, A., see Doehmer, J. **82/83**, 823
Schulte-Hermann, R., W. Bursch, B. Grasl-Kraupp, L. Török, A. Ellinger, L. Müllauer, Role of active cell death (apoptosis) in multi-stage carcinogenesis **82/83**, 143
Schwarz, M., A. Buchmann, K.-W. Bock, Role of cell proliferation at early stages of hepatocarcinogenesis **82/83**, 27
Seidel, A., see Glatt, H. **82/83**, 829
Sequeira, D., see Strobel, H.W. **82/83**, 639
Shankar, S.K., see Ravindranath, V. **82/83**, 633
Shaw, D.R., see Agrawal, S. **82/83**, 431
Shen, S., see Strobel, H.W. **82/83**, 639
Shimoji, M., see Kamataki, T. **82/83**, 879
Shirai, T., see Ito, N. **82/83**, 513
Silbergeld, E.K., The hazards of synthetic (anthropogenic) chemicals **82/83**, 835
Sills, R.C., see Boorman, G.A. **82/83**, 301
Simeon-Rudolf, V., see Reiner, E. **82/83**, 447
Simeonova, P.P., see Luster, M.I. **82/83**, 471
Skrinjaric-Spoljar, M., see Reiner, E. **82/83**, 447
Slater, A.F.G., C. Stefan, I. Nobel, D.J. van den Dobbelsteen, S. Orrenius, Signalling mechanisms and oxidative stress in apoptosis **82/83**, 149

Slijper, M., see Kaptein, R. **82/83**, 591
Smith, A.G., P. Carthew, B. Clothier, D. Constantin, J.E. Francis, S. Madra, Synergy of iron in the toxicity and carcinogenicity of polychlorinated biphenyls (PCBs) and related chemicals **82/83**, 945
Smith, L.L., I.N.H. White, Chemoprevention of breast cancer by tamoxifen: risks and opportunities **82/83**, 181
Soballa, V., see Doehmer, J. **82/83**, 823
Song, J.-H., see Narahashi, T. **82/83**, 239
Spalding, J., see Luster, M.I. **82/83**, 471
Sprinzl, M., see Przybylski, M. **82/83**, 567
Spurgeon, A., The use of neurobehavioural test batteries for research, diagnosis and screening: methodological aspects **82/83**, 191
Squadrito, G.L., see Pryor, W.A. **82/83**, 287
Srivastava, D., see Fox, D.A. **82/83**, 263
Stadler, J., W.A. Schmalix, J. Doehmer, Inhibition of biotransformation by nitric oxide (NO) overproduction and toxic consequences **82/83**, 215
Stefan, C., see Slater, A.F.G. **82/83**, 149
Stevenson, D.E., see Klaunig, J.E. **82/83**, 683
Steyn, P.S., Mycotoxins, general view, chemistry and structure **82/83**, 843
Strobel, H.W., H. Kawashima, J. Geng, D. Sequeira, A. Bergh, A.V. Hodgson, H. Wang, S. Shen, Expression of multiple forms of brain cytochrome P450 **82/83**, 639
Stryd, R.P., see Ulrich, R.G. **82/83**, 107
Sugiyama, Y., see Suzuki, H. **82/83**, 349
Sullivan, F.M., Regulatory and political perspectives in reproductive and developmental hazard assessment **82/83**, 533
Sumpter, J.P., Feminized responses in fish to environmental estrogens **82/83**, 737
Sun, E.L., see Ulrich, R.G. **82/83**, 107
Suzuki, H., T. Iwatsubo, Y. Sugiyama, Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents **82/83**, 349
Swenberg, J.A., D.K. La, N.A. Scheller, K.-y. Wu, Dose-response relationships for carcinogens **82/83**, 751

Takeshita, K., see Utsumi, H. **82/83**, 561
Talalay, P., J.W. Fahey, W.D. Holtzclaw, T. Prestera, Y. Zhang, Chemoprotection against cancer by Phase 2 enzyme induction **82/83**, 173
Tamano, S., see Ito, N. **82/83**, 513
Tatebayashi, H., see Narahashi, T. **82/83**, 239
Taylor, P., Z. Radic, N.A. Hosea, S. Camp, P. Marchot, H.A. Berman, Structural bases for the specificity of cholinesterase catalysis and inhibition **82/83**, 453
Templin, M.V., see Butterworth, B.E. **82/83**, 23
Tewary, H.K., see Iversen, P.L. **82/83**, 425
Thomas, R.S., see Yang, R.S.H. **82/83**, 497
Thompson, L.H., R.W. Wu, J.S. Felton, Genetically modified Chinese hamster ovary (CHO) cells for studying the genotoxicity of heterocyclic amines from cooked foods **82/83**, 883
Tiegs, G., see Bohlinger, I. **82/83**, 227
Tirumalai, P.S., see Ravindranath, V. **82/83**, 633
Török, L., see Schulte-Hermann, R. **82/83**, 143
Tsuchiya, T., see Tsuda, H. **82/83**, 693
Tsuda, H., M. Asamoto, H. Baba-Toriyama, Y. Iwahori, T. Hori, D.J. Kim, T. Tsuchiya, M. Mutai, H. Yamasaki, Clofibrate-induced neoplastic development in the rat liver is associated with decreased connexin 32 expression but not with a co-ordinated shift in expression of marker enzymes **82/83**, 693
Tsuji, R., see Miyamoto, J. **82/83**, 933

Uhlig, S., see Bohlinger, I. **82/83**, 227
Ulrich, R.G., J.A. Bacon, C.T. Cramer, G.W. Peng, D.K. Petrella, R.P. Stryd, E.L. Sun, Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development **82/83**, 107
Urban, P., see Pompon, D. **82/83**, 815
Usherwood, P.N.R., H. Vais, Towards the development of ryanoid insecticides with low mammalian toxicity **82/83**, 247
Utell, M.J., R.J. Looney, Environmentally induced asthma **82/83**, 47
Utsumi, H., K. Ichikawa, K. Takeshita, In vivo ESR measurements of free radical reactions in living mice **82/83**, 561

Vais, H., see Usherwood, P.N.R. **82/83**, 247
van Bladeren, P.J., see Feron, V.J. **82/83**, 505
van Bree, L., M. Marra, H.J. van Scheindelen, P.H. Fischer, S. de Loos, E. Buringh, P.J.A. Rombout, Dose-effect models for ozone exposure: tool for quantitative risk estimation **82/83**, 317
van den Dobbelsteen, D.J., see Slater, A.F.G. **82/83**, 149
van Dorp, C., see Neumann, H.-G. **82/83**, 771
Van Loveren, H., see Vos, J.G. **82/83**, 385
van Scheindelen, H.J., see van Bree, L. **82/83**, 317
van Zorge, J.A., see Feron, V.J. **82/83**, 505
Volk, B., R.P. Meyer, F. von Lintig, B. Ibach, R. Knoth, Localization and characterization of cytochrome P450 in the brain. In vivo and in vitro investigations on phenytoin- and phenobarbital-inducible isoforms **82/83**, 655
von Lintig, F., see Volk, B. **82/83**, 655
Vos, J.G., H. Van Loveren, Markers for immunotoxic effects in rodents and man **82/83**, 385

Walborg Jr., E.F., see Klaunig, J.E. **82/83**, 683
Walker, C.L., see Everitt, J.I. **82/83**, 621
Wang, H., see Strobel, H.W. **82/83**, 639
Ward, J.M., see Gonzalez, F.J. **82/83**, 117
Waterman, M.R., C.M. Jenkins, I. Pikuleva, Genetically engineered bacterial cells and applications **82/83**, 807
Wells, M.S., see White, R.D. **82/83**, 719
Welsch, F., G.M. Blumenthal, R.B. Conolly, Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments **82/83**, 539
Wendel, A., see Bohlinger, I. **82/83**, 227

White, I.N.H., see Smith, L.L. **82/83**, 181
White, R.D., W.C. Daughtrey, M.S. Wells, Health effects of inhaled tertiary amyl methyl ether and ethyl tertiary butyl ether **82/83**, 719
Williamson, A.M., Neurobehavioural test batteries: current status, critical evaluation and new directions **82/83**, 203
Wilmer, J.L., see Luster, M.I. **82/83**, 471
Wink, D.A., J.A. Cook, R. Pacelli, J. Liebmann, M.C. Krishna, J.B. Mitchell, Nitric oxide (NO) protects against cellular damage by reactive oxygen species **82/83**, 221
Winterbourn, C.C., Toxicity of iron and hydrogen peroxide: the Fenton reaction **82/83**, 969
Wolf, D.C., see Butterworth, B.E. **82/83**, 23
Wolf, D.C., see Everitt, J.I. **82/83**, 621
Wu, K.-y., see Swenberg, J.A. **82/83**, 751
Wu, R.W., see Thompson, L.H. **82/83**, 883

Xu, Y., see Klaunig, J.E. **82/83**, 683

Yamasaki, H., see Mesnil, M. **82/83**, 701
Yamasaki, H., see Tsuda, H. **82/83**, 693
Yang, R.S.H., H.A. El-Masri, R.S. Thomas, A.A. Constan, The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures **82/83**, 497
Yokoi, T., see Kamataki, T. **82/83**, 879
Yoshida, T., see Luster, M.I. **82/83**, 471

Zhang, Y., see Talalay, P. **82/83**, 173
Zon, G., Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity **82/83**, 419
Zon, G., see Matsukura, M. **82/83**, 435
Zwirner-Baier, I., see Neumann, H.-G. **82/83**, 771

ELSEVIER

Toxicology Letters 82/83 (1995) 989–994

Toxicology Letters

Subject index

Volumes 82/83 (1995)

Acceptable daily intake (ADI) **82/83**, 513
Acetylaminofluorene **82/83**, 15
Acetylcholinesterase **82/83**, 83, 453
Acetylcysteine **82/83**, 779
Acetyltransferases **82/83**, 627
Active oxygens **82/83**, 561
Activity distribution profiles **82/83**, 447
Adrenal glands (rat) **82/83**, 167
Aeroallergens **82/83**, 47
Aflatoxin **82/83**, 843, 853
Aflatoxin B_1 **82/83**, 861
Ah receptor **82/83**, 117, 731
Air pollution **82/83**, 47
Allergic sensitization **82/83**, 39
Aluminum (Al) **82/83**, 255
Amino-arenes **82/83**, 771
Anthracyclines **82/83**, 395
Anticancer drugs **82/83**, 159
Antidote **82/83**, 785
Antiestrogenicity **82/83**, 731
Antioxidant response element (ARE) **82/83**, 173
Antioxidants **82/83**, 795
Antisense **82/83**, 419, 431
Antisense DNA **82/83**, 435
Antivirals **82/83**, 435
Apoptosis **82/83**, 27, 143, 155, 227, 233, 673
Aquatic ecotoxicology **82/83**, 737
Arachidonic acid metabolism **82/83**, 907
Arachnoid membrane **82/83**, 645
Aromatic amines **82/83**, 627
Artificial fibers **82/83**, 951
Asbestos **82/83**, 483
Asbestos fibers **82/83**, 951
Aspartame **82/83**, 869
Asthma **82/83**, 33, 39, 47, 295
Autoimmunity **82/83**, 385
Autophagic cell death **82/83**, 143

Bcl-2 protein **82/83**, 155
Behavior **82/83**, 203
Benchmark dose **82/83**, 549, 555
Benzene **82/83**, 521
Benzylic alcohols **82/83**, 829
Big Blue® transgenic mouse system **82/83**, 9
Bioassay **82/83**, 301, 663
Biological markers **82/83**, 379
Biomarkers **82/83**, 751
Biomonitoring **82/83**, 65, 757
Biotransformation **82/83**, 823
Bladder carcinogenesis **82/83**, 15
Blood-brain barrier **82/83**, 645, 655
Brain **82/83**, 633
Brain cytochrome P450 **82/83**, 639
Brain drug metabolizing system **82/83**, 639
Brain metabolism **82/83**, 655
Brain P450 isozyme expression **82/83**, 639
Bronchial C-fibers **82/83**, 307
Bronchial hyperresponsiveness **82/83**, 39
Butadiene **82/83**, 521
1,3-Butadiene **82/83**, 607

Calculi **82/83**, 15
Cancer **82/83**, 131, 155
Cancer epidemiology **82/83**, 601
Cancer risk assessment **82/83**, 1
Cancer susceptibility **82/83**, 621
Carbon tetrachloride **82/83**, 561, 891
Carboxylesterase **82/83**, 439
Carcinogenesis **82/83**, 1, 513, 663, 763, 907
Carcinogenicity **82/83**, 301, 853
Carcinogens **82/83**, 751, 757, 835
Catalase **82/83**, 795
Causality **82/83**, 187
cDNA cloning **82/83**, 439
Cell cycle **82/83**, 961
Cell injury **82/83**, 399
Cell proliferation **82/83**, 9, 15, 23, 27
Cell replication **82/83**, 673
Cell-cell communication **82/83**, 701
Ceruloplasmin **82/83**, 941

0378-4274/95/$09.50 © 1995 Elsevier Science Ireland Ltd. All rights reserved

cGMP phosphodiesterase **82/83**, 263
Chelators **82/83**, 951
Chemical exposure **82/83**, 725
Chemical interactions **82/83**, 521, 527
Chemical mixture **82/83**, 497, 513, 527
Chemokines **82/83**, 483
Chimeragenesis **82/83**, 807
Chlordecone **82/83**, 891
Chloroform **82/83**, 23, 901
Cholinesterase **82/83**, 439, 453
Choroid plexuses **82/83**, 645
Chromium **82/83**, 367
CINC **82/83**, 483
Circumventricular organs **82/83**, 645
Clofibrate **82/83**, 693
Closed chamber technique **82/83**, 357
Coagulation **82/83**, 431
Colon cancer **82/83**, 335
Communications media **82/83**, 211
Complement **82/83**, 431
Confounding **82/83**, 187
Connexin 32 **82/83**, 693, 701
Control **82/83**, 187
Crocidolite **82/83**, 483
Cultured cells **82/83**, 879
Cyanide antidotes **82/83**, 795
Cytochrome P450 **82/83**, 73, 83, 215, 633, 655, 823, 861
Cytokines **82/83**, 215

Dentate **82/83**, 271
Dermatotoxicity **82/83**, 471
Desferrioxamine **82/83**, 779
Developmental toxicity **82/83**, 549, 555, 743
Diabetogenesis **82/83**, 99
Diagnosis **82/83**, 191
Diaminotoluenes **82/83**, 9
9,21-Didehydroryanodol **82/83**, 247
Dieldrin **82/83**, 239, 683
Diethylnitrosamine **82/83**, 751
Digitalis **82/83**, 785
Dimethylnitrosamine **82/83**, 751
Dioxin **82/83**, 27, 117, 341, 373, 743, 835
Dioxin receptor **82/83**, 465
Disability **82/83**, 197
Dithiocarbamate **82/83**, 149
DNA adduct **82/83**, 323, 627, 751, 757
DNA damage **82/83**, 181, 425
DNA fragmentation **82/83**, 233
DNA methylation **82/83**, 663
DNA methyltransferase activity **82/83**, 335
DNA repair **82/83**, 883
DNA-binding proteins **82/83**, 577
Dose-response **82/83**, 751
Dose-response for tissue repair **82/83**, 891
Dosimetry modeling **82/83**, 919
Dosimetry models **82/83**, 277
Double-blind **82/83**, 187
Double-stranded oligonucleotides **82/83**, 567
Doxorubicin **82/83**, 395
Drug **82/83**, 107
Drug metabolism **82/83**, 349, 633
Drug metabolizing enzyme **82/83**, 439, 645
Drug toxicity **82/83**, 159
Drug-specific antibody **82/83**, 801

E. coli **82/83**, 807
Electrophile response element (EpRE) **82/83**, 173
Electrospray-ionization mass spectrometry **82/83**, 567
Enantiomeric inhibitors **82/83**, 453
Endocrine disruption **82/83**, 743
Endotoxin **82/83**, 477
Environment **82/83**, 33
Environmental controls **82/83**, 47
Enzyme **82/83**, 693
Epidemiology **82/83**, 33
Epidermal cytokines **82/83**, 491
Epigenetic **82/83**, 663
Epithelial cell lining fluid **82/83**, 287
Epithelial dysfunction **82/83**, 295
Epoxide **82/83**, 861
Error rate **82/83**, 187
ESR **82/83**, 561
Esterase **82/83**, 83, 933
Esterase purification **82/83**, 459
Esterases **82/83**, 83
Estrogenic chemicals **82/83**, 737
ETBE **82/83**, 719
Ethyl tertiary butyl ether **82/83**, 713
Ethylene glycol ether teratogenicity **82/83**, 539
Experimental doubt **82/83**, 187
Exposure assessment **82/83**, 763
Exposure control **82/83**, 771
Exposure-dose-response models **82/83**, 317
Extrapolation **82/83**, 341

Fasciculin **82/83**, 453
Fenton reaction **82/83**, 969
Ferritin **82/83**, 941
Fish **82/83**, 737
FK 506 **82/83**, 99
Flavin-containing monooxygenase (FMO) **82/83**, 73, 633
Flavodoxin **82/83**, 807
Flexibility and dynamics **82/83**, 591
Flumazenil **82/83**, 779
Foetal weight **82/83**, 555
Folate **82/83**, 707
Forensic **82/83**, 197
Formate **82/83**, 707
Free radical **82/83**, 561
Free radical release **82/83**, 951
Fumonisins **82/83**, 853

GABA gated Cl^--channel **82/83**, 83
GABA receptor **82/83**, 239

GABA receptor subunits **82/83**, 239
Galactosamine **82/83**, 227
Gap junctions **82/83**, 701
Gas transport **82/83**, 277
Gene expression **82/83**, 91
Gene mutation **82/83**, 323
Gene-specific therapeutics **82/83**, 425
Genetic predispositon **82/83**, 323
Genetically engineered cells **82/83**, 879
Genotoxic **82/83**, 663
Genotoxicity **82/83**, 131, 181, 869
Germline mutations **82/83**, 601
Gliomas **82/83**, 601
Glucocorticoid receptor **82/83**, 465
Glutamate-induced cell activation **82/83**, 399
Glutathione **82/83**, 149
Glutathione peroxidase **82/83**, 395
Glutathione S-transferases **82/83**, 83
Glutathione transferases **82/83**, 173

H-ras oncogene **82/83**, 123
Haemodynamics **82/83**, 779
Hazard index **82/83**, 527
HBV **82/83**, 435
Hemoglobin adducts **82/83**, 771
Hepatic fibrosis **82/83**, 117
Hepatic peroxisome proliferation **82/83**, 673
Hepatic porphyria **82/83**, 945
Hepatocarcinogen **82/83**, 843
Hepatocarcinogenesis **82/83**, 27, 413, 673
Hepatocyte **82/83**, 107
Hepatotoxicity **82/83**, 107, 901
Heterocyclic amines **82/83**, 883
Heterologous expression **82/83**, 823, 829
HIV **82/83**, 435
hprt locus **82/83**, 323
Human **82/83**, 65
Human chamber exposure **82/83**, 713
Human P450 and epoxide hydrolase **82/83**, 815
Human pregnancy extrapolations **82/83**, 539
Human serum paraoxonases and cholinesterases **82/83**, 447
Human subjects **82/83**, 295
Human T lymphocytes **82/83**, 323
Humans **82/83**, 521
Hycanthone **82/83**, 829
Hydrogen peroxide **82/83**, 395
8-Hydroxydeoxyguanosine **82/83**, 413
Hydroxyl radical toxicity **82/83**, 969
Hydroxypyridinones **82/83**, 961
Hydroxyurea **82/83**, 167
Hypothesis generating/testing **82/83**, 187

ICE **82/83**, 477
ICE-like proteases **82/83**, 149
IL-1 **82/83**, 477
IL-12 **82/83**, 477
Immune suppression **82/83**, 385
Immunosuppressants **82/83**, 99
Immunotherapy **82/83**, 801
Immunotoxicity testing **82/83**, 385
Immunotoxicology **82/83**, 385
In vitro **82/83**, 107
In vitro/in vivo scaling **82/83**, 349
In vivo mutations **82/83**, 131
Inbred mice **82/83**, 295
Indoor air pollution **82/83**, 33
Inflammation **82/83**, 215, 287, 295
Inflammatory cytokines **82/83**, 471
Inhalation toxicity **82/83**, 919
Inhalation toxicokinetics **82/83**, 357
Inhibitors of genetic expression **82/83**, 419
Initiation **82/83**, 413
Insect muscle **82/83**, 247
Insulin biosynthesis **82/83**, 99
Interaction with ligands **82/83**, 447
Interferon **82/83**, 477
Interleukin-1 **82/83**, 167, 227
Interleukin-1α **82/83**, 907
Interleukin-1β **82/83**, 135
Interleukin-4 **82/83**, 167
Internal dose **82/83**, 373
Interspecies extrapolation **82/83**, 357
IQ **82/83**, 883
Iron **82/83**, 941, 945
Iron chelators **82/83**, 961
Iron mediated injury **82/83**, 969
Iron mobilization **82/83**, 951
Iron toxicity **82/83**, 951
Irritancy **82/83**, 907

Journalism **82/83**, 211

Keratinocyte-derived cytokines **82/83**, 471
Keratinocytes **82/83**, 907
Kinases **82/83**, 159
Knockout-mice **82/83**, 477

Lac operator **82/83**, 591
Lac repressor **82/83**, 591
lacI **82/83**, 607
Langerhans cells **82/83**, 491
Lead (Pb) **82/83**, 255
Lead **82/83**, 263, 367, 399
Learning **82/83**, 271
Leucine zipper polypeptides **82/83**, 567
Lipase **82/83**, 287
Lipid ozonation product **82/83**, 287
Lipid peroxidation **82/83**, 941
Liquid/air partition coefficients **82/83**, 713
Litigation **82/83**, 197
Liver **82/83**, 107, 143, 215, 655
Liver cancer **82/83**, 861, 945
Liver carcinogenesis **82/83**, 613
Liver injury **82/83**, 227

Liver tumor **82/83**, 181, 693
Lung **82/83**, 301, 919
Lung cancer **82/83**, 335
Lung function **82/83**, 307, 317
Lung inflammation **82/83**, 307

Macrophage inflammatory proteins **82/83**, 483
Magnesium **82/83**, 263
Malignant conversion **82/83**, 123
Man **82/83**, 385
Markers of effects **82/83**, 379
Markers of exposure **82/83**, 379
Maximum tolerated doses **82/83**, 891
MCF-7 cells **82/83**, 143
Mechanism-based model **82/83**, 901
Mechanisms **82/83**, 779
Medium-term bioassay **82/83**, 513
Menadione **82/83**, 413
Mercury (Hg) **82/83**, 255
Metabolic activation **82/83**, 883
Metabolism **82/83**, 181
Metalloenzymes **82/83**, 961
Metals **82/83**, 367, 835
Methanol **82/83**, 707
2-Methoxyacetic acid **82/83**, 539
2-Methoxyethanol developmental toxicity **82/83**, 539
Methyl tertiary amyl ether **82/83**, 713
Methyl tertiary butyl ether **82/83**, 713
Methylenedioxyphenyl compounds **82/83**, 73
Methylmercury (MeHg) **82/83**, 255
4-Methylpyrazole **82/83**, 785
Mice **82/83**, 521, 613
Modeling **82/83**, 379
Molecular biomarkers **82/83**, 763
Molecular epidemiology **82/83**, 763
Molecular mechanisms of toxicity **82/83**, 419
Monooxygenase **82/83**, 633
Mouse diaphragm muscle **82/83**, 247
MTBE **82/83**, 719
Multistage carcinogenesis **82/83**, 701
Mutagenesis **82/83**, 1, 131, 883
Mutagenic carcinogens **82/83**, 9
Mutagenic noncarcinogens **82/83**, 9
Mutation spectrum **82/83**, 607
Mycotoxicosis **82/83**, 843
Mycotoxin **82/83**, 843, 853, 861

N-acetylcysteine **82/83**, 785
Na^+-channel **82/83**, 83
Naloxone **82/83**, 779
Necrosis **82/83**, 149, 227
Neoplasia **82/83**, 301, 725
Nephrotoxicity **82/83**, 99, 869
Neuro-oncogenesis **82/83**, 601
Neurobehavioral assessment **82/83**, 197
Neurobehavioral methods **82/83**, 203
Neurobehavioural tests **82/83**, 191
Neuronal cells **82/83**, 399
Neuropathy promotion **82/83**, 459
Neuropathy target esterase **82/83**, 459
Neuropsychology **82/83**, 197
Neurotoxic **82/83**, 197
Neurotoxicity **82/83**, 795
Neutrophils **82/83**, 483
Nitric oxide **82/83**, 215, 221, 233, 795
Nitric oxide synthase **82/83**, 233
Nitro-arenes **82/83**, 771
Nitropropanes **82/83**, 9
Nitroso compounds **82/83**, 601
NMDA-activated channel currents (NACCs) **82/83**, 255
NMR spectroscopy **82/83**, 577, 591
NO-donor **82/83**, 233
Non-genotoxic carcinogens **82/83**, 143
Non-human primates **82/83**, 707
Noncancer risk assessment **82/83**, 901
Nongenotoxic **82/83**, 663
Nongenotoxic carcinogen **82/83**, 23
Nongenotoxic carcinogenesis **82/83**, 683
Nose **82/83**, 919
NSAID **82/83**, 907

Occupational exposure **82/83**, 39
Ochratoxin A **82/83**, 861, 869
Oligodeoxynucleotides **82/83**, 419
Oligonucleotides **82/83**, 431
Oral activity **82/83**, 961
Organophosphates **82/83**, 9, 453
Organophosphorus neuropathy protection **82/83**, 459
Outdoor air pollution **82/83**, 33
Oxidant air pollution **82/83**, 317
Oxidative damage **82/83**, 561
Oxidative stress **82/83**, 221, 399, 413, 673, 683, 941
Oxygen radicals **82/83**, 221, 407
Oxygenate **82/83**, 719
Ozone **82/83**, 277, 287, 301, 307
Ozone exposure **82/83**, 317

P450 expression **82/83**, 807
P450c17 **82/83**, 807
P450scc **82/83**, 807
p53 **82/83**, 155, 601
p53 mRNA **82/83**, 425
p53 tumor suppressor gene **82/83**, 1
p53 Tumour suppressor gene **82/83**, 123
Papilloma **82/83**, 123
Passive dosimetry **82/83**, 65
PB-PK models **82/83**, 341
PBK models **82/83**, 367
PBPK/PD modeling **82/83**, 497
PC12 cell **82/83**, 795
PCBs **82/83**, 835, 945
Peroxisome proliferators **82/83**, 117
Peroxisomes **82/83**, 673
Pesticide **82/83**, 65, 513, 725

Pesticide poisoning **82/83**, 55
Pesticide-metabolizing enzymes **82/83**, 73
Pesticides **82/83**, 83
Phagocytosis **82/83**, 951
Pharmacodynamics **82/83**, 379, 497
Pharmacokinetics **82/83**, 341, 497
Phenobarbital **82/83**, 655
Phenotypes **82/83**, 447
Phenylalanine **82/83**, 869
Phenytoin **82/83**, 655
PhIP **82/83**, 883
Phorate **82/83**, 73
Phospholipase **82/83**, 287
Phosphorothioate **82/83**, 419, 431
Phosphorothioate oligonucleotides **82/83**, 425
Phototransduction **82/83**, 263
Physiological models **82/83**, 521
Physiologically based pharmacokinetic model **82/83**, 349
Physiologically based pharmacokinetics **82/83**, 539
Physiologically-based toxicokinetic model for gas uptake studies **82/83**, 357
Placental transfer **82/83**, 975
Polychlorinated biphenyls (PCBs) **82/83**, 465, 743
Polycyclic aromatic hydrocarbons **82/83**, 627
Polymorphisms **82/83**, 627
Polysialylation **82/83**, 271
Potassium channels **82/83**, 247
PPAR **82/83**, 465
Preclinical pharmacology **82/83**, 425
Pregnancy risk **82/83**, 539
Progression **82/83**, 413
Proliferation **82/83**, 271
Promotion **82/83**, 413, 663, 673
Proteases **82/83**, 135
Protein adduct **82/83**, 757
Protein kinase C **82/83**, 399
Protein-DNA interaction **82/83**, 591
Protein-nucleotide interactions **82/83**, 567
Public health **82/83**, 527
Pulmonary function **82/83**, 295
Pyrethroids **82/83**, 239, 933

Quantitative **82/83**, 901
Quinone reductase **82/83**, 173

ras mutations **82/83**, 27
Rat **82/83**, 413, 513, 693
Rats **82/83**, 505, 521
Receptor-mediated toxicity **82/83**, 465, 743
Receptors **82/83**, 91
Redox enzyme **82/83**, 413
Reduced uncertainty **82/83**, 901
Reference range levels **82/83**, 373
Regulatory toxicology **82/83**, 533
Relation to diseases **82/83**, 447
Renal carcinoma **82/83**, 621
Reproduction **82/83**, 725
Reproductive system **82/83**, 533
Research **82/83**, 191
Resistance **82/83**, 613
Respiratory health effects **82/83**, 307
Respiratory tract absorption **82/83**, 277
Retina **82/83**, 263
Retinoic acid **82/83**, 975
Retinoid **82/83**, 91
Retinoid receptor ligands **82/83**, 975
Retinoids **82/83**, 341
Retinoyl-β-glucuronides **82/83**, 975
Retroviral vectors **82/83**, 601
Risk assessment **82/83**, 23, 65, 341, 521, 533, 549, 663, 771, 835, 853, 891, 919, 933
Risk management **82/83**, 65
Risk reporting **82/83**, 211
Rod photoreceptor **82/83**, 263
Rodent gestation **82/83**, 539
Rodents **82/83**, 385
ROS **82/83**, 149
Ryanodine **82/83**, 247

Safety **82/83**, 725
Safety assessment **82/83**, 341
Safrole **82/83**, 829
Salmonella typhimurium **82/83**, 829
Screening **82/83**, 191
Selective toxicity **82/83**, 239
Selenium **82/83**, 395
Sensitization **82/83**, 491
Serine hydrolase **82/83**, 453
Signal transduction **82/83**, 407
Silica **82/83**, 483
Similar/different target organs/mode of action **82/83**, 505
Simple mixtures **82/83**, 505
Simulation **82/83**, 815
Skin immunity **82/83**, 471
Skin paresthesia **82/83**, 933
Sodium channel **82/83**, 239, 933
Sodium nitroprusside **82/83**, 227
Sodium saccharin **82/83**, 15
Solvents **82/83**, 197
Species differences **82/83**, 673
Squamous carcinoma **82/83**, 123
Structure determination **82/83**, 577
Structure-activity relationships **82/83**, 99
Styrene **82/83**, 521
Sulfotransferase **82/83**, 829
Suppressor gene **82/83**, 621
Supramolecular protein complexes **82/83**, 567
Susceptibility **82/83**, 613
Synthetic chemicals **82/83**, 835

T helper cells **82/83**, 491
TAME **82/83**, 719
Tamoxifen **82/83**, 181
TCDD **82/83**, 27, 731

Teratogenesis **82/83**, 975
Teratogenicity **82/83**, 91
Tertiary butyl alcohol **82/83**, 713
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) **82/83**, 743
Thioacetamide **82/83**, 891
Thymocyte **82/83**, 149
Thymocyte apoptosis **82/83**, 135
Tissue repair **82/83**, 891
TLCK **82/83**, 135
TNF **82/83**, 477
Toxic epidemiology **82/83**, 55
Toxic outbreak **82/83**, 55
Toxicity **82/83**, 301
Toxicity assessment **82/83**, 527
Toxicodynamics **82/83**, 785
Toxicokinetic two-compartment model with physiological gas uptake **82/83**, 357
Toxicokinetics **82/83**, 379, 785
Toxicology **82/83**, 211
Transcription factor 1 **82/83**, 577
Transcription factor NF-κB **82/83**, 407
Transgene **82/83**, 607, 879
Transgenic animal **82/83**, 131
Transgenic mice **82/83**, 879
Triazole **82/83**, 555
1,2,3-Trichloropropane **82/83**, 751
Tricyclic antidepressant **82/83**, 801
Tumor necrosis factor **82/83**, 167
Tumor progression **82/83**, 335
Tumor promotion **82/83**, 143
Tumor suppressor p53 **82/83**, 233
Tumor suppressos **82/83**, 701
Tumour stem cell **82/83**, 123
Type II cells **82/83**, 335

Uptake **82/83**, 277
Uranium **82/83**, 367
Urinary bladder **82/83**, 627

V79 cells **82/83**, 829
Vegetables **82/83**, 173
Vinyl chloride **82/83**, 751
Vinyl fluoride **82/83**, 751
Viral oncogenes **82/83**, 601
Vitamin A **82/83**, 975
Vitamin E **82/83**, 683
Vitellogenin **82/83**, 737
VOCs **82/83**, 373
Voltage-activated calcium channel currents (VACCCs) **82/83**, 255

Xenobiotics **82/83**, 823
Xenoestrogens **82/83**, 835

Yeast heterologous expression **82/83**, 815

Zinc (Zn) **82/83**, 255